Merck's TIGIT/PD-1 combo disappoints in lung cancer trial
TL;DR Summary
Merck has released the full results of its Phase II lung cancer study, revealing that its TIGIT/PD-1 combination therapy failed to meet both primary and secondary endpoints. Despite this setback, Merck will continue with its Phase III studies for the candidate, a co-formulation of vibostolimab and Keytruda, with the first readout expected in 2025. The data from the Phase II trial will inform the program moving forward.
- Merck details PhII TIGIT/PD-1 fail in lung cancer Endpoints News
- Merck's lung cancer drug combo fails trial in setback for new therapy class Reuters
- Merck & Co. digs into TIGIT fail, sharing survival data from phase 2 lung cancer trial FierceBiotech
- Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
0 min
vs 1 min read
Condensed
48%
128 → 67 words
Want the full story? Read the original article
Read on Endpoints News